| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Crohn Disease | 49 | 2020 | 959 | 10.32 | Why? |
| Colitis, Ulcerative | 41 | 2020 | 1037 | 8.85 | Why? |
| Inflammatory Bowel Diseases | 55 | 2021 | 3209 | 8.42 | Why? |
| Biosimilar Pharmaceuticals | 18 | 2019 | 205 | 6.04 | Why? |
| Mesalamine | 7 | 2019 | 89 | 4.56 | Why? |
| Infliximab | 22 | 2019 | 502 | 3.68 | Why? |
| Gastrointestinal Agents | 19 | 2020 | 393 | 3.36 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 11 | 2019 | 1454 | 1.79 | Why? |
| Tumor Necrosis Factor-alpha | 21 | 2019 | 2483 | 1.76 | Why? |
| Colitis | 5 | 2019 | 266 | 1.71 | Why? |
| Biological Products | 9 | 2019 | 2331 | 1.64 | Why? |
| Pyrroles | 5 | 2018 | 292 | 1.56 | Why? |
| Ustekinumab | 5 | 2019 | 216 | 1.52 | Why? |
| Biological Therapy | 6 | 2018 | 456 | 1.51 | Why? |
| Budesonide | 3 | 2019 | 192 | 1.38 | Why? |
| Intestinal Mucosa | 8 | 2021 | 1046 | 1.32 | Why? |
| Antibodies, Monoclonal, Humanized | 17 | 2019 | 9335 | 1.29 | Why? |
| Rectal Fistula | 4 | 2019 | 38 | 1.29 | Why? |
| Constriction, Pathologic | 5 | 2019 | 212 | 1.26 | Why? |
| Piperidines | 5 | 2018 | 795 | 1.23 | Why? |
| Immunosuppressive Agents | 12 | 2021 | 6331 | 1.22 | Why? |
| Intestines | 5 | 2019 | 817 | 1.21 | Why? |
| Colonoscopy | 4 | 2018 | 738 | 1.14 | Why? |
| Antibodies, Monoclonal | 17 | 2019 | 8041 | 1.13 | Why? |
| Intestinal Fistula | 3 | 2019 | 43 | 1.11 | Why? |
| Pyrimidines | 5 | 2018 | 1557 | 1.09 | Why? |
| Remission Induction | 18 | 2019 | 950 | 1.02 | Why? |
| Antibodies | 3 | 2019 | 846 | 1.01 | Why? |
| Colon | 3 | 2018 | 669 | 1.00 | Why? |
| Adalimumab | 9 | 2019 | 389 | 0.96 | Why? |
| Janus Kinase Inhibitors | 2 | 2018 | 682 | 0.96 | Why? |
| Proctocolectomy, Restorative | 2 | 2019 | 51 | 0.92 | Why? |
| Interleukin-23 | 4 | 2018 | 64 | 0.90 | Why? |
| Anti-Inflammatory Agents | 7 | 2020 | 6153 | 0.88 | Why? |
| Janus Kinases | 4 | 2019 | 414 | 0.79 | Why? |
| Pouchitis | 1 | 2019 | 20 | 0.77 | Why? |
| Matrix Metalloproteinase Inhibitors | 1 | 2018 | 45 | 0.76 | Why? |
| Fibrosis | 3 | 2019 | 800 | 0.75 | Why? |
| Interleukin-23 Subunit p19 | 1 | 2018 | 26 | 0.74 | Why? |
| Integrin alpha4 | 1 | 2018 | 21 | 0.73 | Why? |
| Reproductive Behavior | 1 | 2018 | 22 | 0.73 | Why? |
| Induction Chemotherapy | 3 | 2019 | 149 | 0.72 | Why? |
| Mercaptopurine | 2 | 2017 | 68 | 0.72 | Why? |
| Lysophospholipids | 1 | 2018 | 74 | 0.70 | Why? |
| Sphingosine | 1 | 2018 | 101 | 0.68 | Why? |
| Pyoderma Gangrenosum | 1 | 2017 | 41 | 0.66 | Why? |
| Erythema Nodosum | 1 | 2017 | 38 | 0.65 | Why? |
| Sweet Syndrome | 1 | 2017 | 54 | 0.64 | Why? |
| Stem Cell Transplantation | 2 | 2019 | 531 | 0.63 | Why? |
| Adipose Tissue | 2 | 2019 | 612 | 0.63 | Why? |
| Tumor Suppressor Proteins | 1 | 2017 | 165 | 0.63 | Why? |
| Endothelial Progenitor Cells | 1 | 2017 | 103 | 0.63 | Why? |
| Urea | 1 | 2017 | 228 | 0.62 | Why? |
| Patient Care Planning | 2 | 2018 | 582 | 0.62 | Why? |
| Membrane Transport Proteins | 1 | 2017 | 152 | 0.62 | Why? |
| Phosphodiesterase 4 Inhibitors | 1 | 2017 | 112 | 0.62 | Why? |
| Antibodies, Blocking | 1 | 2017 | 174 | 0.61 | Why? |
| Protein Kinase Inhibitors | 4 | 2018 | 1585 | 0.61 | Why? |
| Anemia, Iron-Deficiency | 1 | 2018 | 210 | 0.61 | Why? |
| Humans | 154 | 2021 | 930598 | 0.61 | Why? |
| Wound Healing | 2 | 2019 | 424 | 0.61 | Why? |
| Docosahexaenoic Acids | 1 | 2017 | 145 | 0.60 | Why? |
| Magnetic Resonance Imaging | 6 | 2019 | 6551 | 0.59 | Why? |
| Secondary Prevention | 3 | 2017 | 762 | 0.59 | Why? |
| Quality Assurance, Health Care | 1 | 2020 | 596 | 0.59 | Why? |
| Integrins | 5 | 2019 | 158 | 0.57 | Why? |
| Immunotherapy | 2 | 2019 | 2421 | 0.56 | Why? |
| Helicobacter Infections | 1 | 2017 | 216 | 0.56 | Why? |
| Multimodal Imaging | 1 | 2019 | 534 | 0.55 | Why? |
| Helicobacter pylori | 1 | 2017 | 262 | 0.55 | Why? |
| Thalidomide | 1 | 2017 | 247 | 0.55 | Why? |
| Diverticulum, Colon | 1 | 2013 | 4 | 0.55 | Why? |
| Endothelium | 1 | 2018 | 460 | 0.55 | Why? |
| Endoscopy, Gastrointestinal | 5 | 2020 | 1545 | 0.55 | Why? |
| Breath Tests | 1 | 2017 | 338 | 0.54 | Why? |
| Double-Blind Method | 13 | 2019 | 5988 | 0.53 | Why? |
| Biological Factors | 1 | 2017 | 276 | 0.51 | Why? |
| Lymphoma | 1 | 2018 | 522 | 0.51 | Why? |
| Hospital Units | 1 | 2020 | 1017 | 0.51 | Why? |
| Data Accuracy | 1 | 2018 | 715 | 0.50 | Why? |
| Hospital Departments | 1 | 2020 | 831 | 0.49 | Why? |
| General Practitioners | 1 | 2020 | 568 | 0.49 | Why? |
| Ultrasonography | 2 | 2018 | 4409 | 0.47 | Why? |
| Treatment Outcome | 34 | 2020 | 51732 | 0.47 | Why? |
| Drug Eruptions | 1 | 2017 | 319 | 0.47 | Why? |
| Patient Care Management | 2 | 2020 | 1514 | 0.47 | Why? |
| Interleukin-13 Receptor alpha2 Subunit | 1 | 2011 | 3 | 0.46 | Why? |
| Diarrhea | 3 | 2020 | 2743 | 0.46 | Why? |
| Th17 Cells | 1 | 2017 | 657 | 0.45 | Why? |
| Metabolic Syndrome | 1 | 2019 | 810 | 0.44 | Why? |
| Gastrointestinal Diseases | 3 | 2021 | 2580 | 0.43 | Why? |
| Inflammation | 5 | 2020 | 13255 | 0.43 | Why? |
| Pneumonia, Viral | 26 | 2020 | 243684 | 0.42 | Why? |
| Coronavirus Infections | 26 | 2020 | 253789 | 0.41 | Why? |
| Colorectal Neoplasms | 4 | 2019 | 1884 | 0.40 | Why? |
| Italy | 18 | 2021 | 38444 | 0.40 | Why? |
| Interleukin-13 | 1 | 2011 | 204 | 0.39 | Why? |
| Digestive System Surgical Procedures | 4 | 2019 | 677 | 0.37 | Why? |
| Sexual Behavior | 1 | 2018 | 1322 | 0.36 | Why? |
| Betacoronavirus | 24 | 2020 | 204454 | 0.36 | Why? |
| Clinical Trials as Topic | 9 | 2020 | 7330 | 0.36 | Why? |
| Interleukin-12 | 3 | 2018 | 156 | 0.36 | Why? |
| Drug Design | 2 | 2018 | 2627 | 0.36 | Why? |
| Infection Control | 6 | 2020 | 23131 | 0.35 | Why? |
| Practice Patterns, Physicians' | 4 | 2020 | 4927 | 0.34 | Why? |
| T-Lymphocytes, Helper-Inducer | 1 | 2011 | 497 | 0.33 | Why? |
| Health Services Needs and Demand | 2 | 2019 | 3419 | 0.33 | Why? |
| Attitude to Health | 1 | 2020 | 2002 | 0.32 | Why? |
| Epitopes | 2 | 2018 | 4113 | 0.32 | Why? |
| Glucocorticoids | 4 | 2019 | 4431 | 0.31 | Why? |
| Inflammation Mediators | 2 | 2021 | 2654 | 0.31 | Why? |
| Diffusion Magnetic Resonance Imaging | 2 | 2018 | 317 | 0.31 | Why? |
| Gastrointestinal Microbiome | 2 | 2018 | 1961 | 0.30 | Why? |
| Lymphocytes | 1 | 2019 | 3056 | 0.30 | Why? |
| Pandemics | 28 | 2021 | 389249 | 0.30 | Why? |
| Adult | 46 | 2020 | 244371 | 0.30 | Why? |
| Predictive Value of Tests | 7 | 2019 | 9537 | 0.30 | Why? |
| Consensus | 3 | 2019 | 6345 | 0.30 | Why? |
| Intestinal Obstruction | 2 | 2019 | 197 | 0.30 | Why? |
| Probiotics | 1 | 2013 | 694 | 0.30 | Why? |
| Molecular Targeted Therapy | 4 | 2018 | 1579 | 0.29 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 4 | 2020 | 9706 | 0.29 | Why? |
| Medication Adherence | 4 | 2019 | 1270 | 0.29 | Why? |
| Disease Management | 6 | 2020 | 6841 | 0.29 | Why? |
| Endoscopy, Digestive System | 2 | 2020 | 352 | 0.28 | Why? |
| Cell Movement | 2 | 2019 | 695 | 0.28 | Why? |
| Azathioprine | 2 | 2017 | 161 | 0.28 | Why? |
| Patient Satisfaction | 1 | 2017 | 2517 | 0.28 | Why? |
| Homocysteine | 1 | 2005 | 83 | 0.28 | Why? |
| Skin | 1 | 2017 | 2096 | 0.27 | Why? |
| Severity of Illness Index | 13 | 2019 | 48226 | 0.27 | Why? |
| Delphi Technique | 2 | 2018 | 1257 | 0.26 | Why? |
| Feces | 5 | 2020 | 4235 | 0.25 | Why? |
| Drug Approval | 3 | 2019 | 1325 | 0.25 | Why? |
| Quality of Life | 9 | 2019 | 9820 | 0.25 | Why? |
| Skin Neoplasms | 1 | 2017 | 1679 | 0.25 | Why? |
| Recurrence | 5 | 2020 | 3675 | 0.25 | Why? |
| Female | 51 | 2021 | 380317 | 0.24 | Why? |
| Gastroenterology | 3 | 2020 | 1352 | 0.24 | Why? |
| Infectious Disease Transmission, Professional-to-Patient | 2 | 2020 | 1316 | 0.24 | Why? |
| Telemedicine | 4 | 2021 | 25032 | 0.23 | Why? |
| Mucoproteins | 2 | 2018 | 32 | 0.23 | Why? |
| Surgical Procedures, Operative | 2 | 2019 | 2662 | 0.23 | Why? |
| Cross Reactions | 3 | 2018 | 4374 | 0.23 | Why? |
| Algorithms | 2 | 2018 | 7346 | 0.23 | Why? |
| Dextran Sulfate | 2 | 2018 | 54 | 0.22 | Why? |
| Signal Transduction | 5 | 2018 | 7207 | 0.22 | Why? |
| Male | 44 | 2021 | 367725 | 0.21 | Why? |
| Postoperative Complications | 2 | 2019 | 5861 | 0.21 | Why? |
| Nervous System Diseases | 1 | 2019 | 4092 | 0.21 | Why? |
| Proctitis | 1 | 2019 | 16 | 0.21 | Why? |
| Arthritis | 2 | 2019 | 288 | 0.21 | Why? |
| Vascular Endothelial Growth Factor C | 1 | 2019 | 8 | 0.21 | Why? |
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2019 | 8 | 0.21 | Why? |
| Ileitis | 1 | 2019 | 21 | 0.21 | Why? |
| Patient-Centered Care | 2 | 2019 | 860 | 0.20 | Why? |
| Leukocyte L1 Antigen Complex | 2 | 2019 | 238 | 0.20 | Why? |
| Tumor Escape | 1 | 2019 | 36 | 0.20 | Why? |
| Conization | 1 | 2019 | 4 | 0.20 | Why? |
| Animals | 13 | 2019 | 78931 | 0.20 | Why? |
| Patient Acuity | 4 | 2020 | 1755 | 0.20 | Why? |
| Middle Aged | 32 | 2021 | 270681 | 0.20 | Why? |
| Squamous Intraepithelial Lesions of the Cervix | 1 | 2019 | 21 | 0.20 | Why? |
| Randomized Controlled Trials as Topic | 7 | 2019 | 10649 | 0.20 | Why? |
| Fatigue | 3 | 2019 | 2479 | 0.20 | Why? |
| Gestational Trophoblastic Disease | 1 | 2018 | 8 | 0.19 | Why? |
| Uterine Prolapse | 1 | 2018 | 5 | 0.19 | Why? |
| Immunologic Factors | 4 | 2020 | 4206 | 0.19 | Why? |
| Receptors, Lysosphingolipid | 1 | 2018 | 25 | 0.19 | Why? |
| Metronidazole | 1 | 2019 | 59 | 0.19 | Why? |
| Economics, Pharmaceutical | 1 | 2019 | 61 | 0.19 | Why? |
| Nocebo Effect | 1 | 2018 | 18 | 0.19 | Why? |
| Abdominal Abscess | 1 | 2018 | 41 | 0.19 | Why? |
| Oxadiazoles | 1 | 2018 | 41 | 0.18 | Why? |
| Indans | 1 | 2018 | 54 | 0.18 | Why? |
| Epoxy Compounds | 1 | 2017 | 21 | 0.18 | Why? |
| Osteoporosis | 2 | 2019 | 410 | 0.18 | Why? |
| Cholangitis, Sclerosing | 1 | 2019 | 106 | 0.18 | Why? |
| Cell Adhesion Molecules | 2 | 2018 | 472 | 0.18 | Why? |
| Fetal Membranes, Premature Rupture | 1 | 2019 | 122 | 0.18 | Why? |
| Sexual Dysfunctions, Psychological | 1 | 2018 | 37 | 0.18 | Why? |
| Clinical Trials, Phase II as Topic | 2 | 2018 | 801 | 0.18 | Why? |
| Triggering Receptor Expressed on Myeloid Cells-1 | 1 | 2018 | 40 | 0.18 | Why? |
| Comparative Effectiveness Research | 1 | 2018 | 178 | 0.18 | Why? |
| Oxylipins | 1 | 2017 | 29 | 0.18 | Why? |
| Drug Substitution | 3 | 2018 | 385 | 0.18 | Why? |
| Follow-Up Studies | 6 | 2021 | 17020 | 0.18 | Why? |
| Hypogastric Plexus | 1 | 2017 | 4 | 0.18 | Why? |
| Antimetabolites, Antineoplastic | 1 | 2018 | 99 | 0.18 | Why? |
| Cervical Intraepithelial Neoplasia | 1 | 2019 | 114 | 0.18 | Why? |
| Carbon Isotopes | 1 | 2017 | 141 | 0.17 | Why? |
| Ciprofloxacin | 1 | 2019 | 130 | 0.17 | Why? |
| Postoperative Period | 2 | 2017 | 651 | 0.17 | Why? |
| Sulfhydryl Compounds | 1 | 2018 | 104 | 0.17 | Why? |
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2017 | 65 | 0.17 | Why? |
| Young Adult | 17 | 2020 | 93724 | 0.17 | Why? |
| Immunity, Mucosal | 1 | 2021 | 426 | 0.17 | Why? |
| Delayed-Action Preparations | 1 | 2019 | 291 | 0.17 | Why? |
| Matrix Metalloproteinase 9 | 1 | 2018 | 211 | 0.17 | Why? |
| Methotrexate | 2 | 2018 | 471 | 0.17 | Why? |
| Tablets | 1 | 2017 | 219 | 0.17 | Why? |
| Risk Factors | 13 | 2021 | 71621 | 0.17 | Why? |
| Surgical Stomas | 1 | 2017 | 33 | 0.17 | Why? |
| Symporters | 1 | 2017 | 80 | 0.17 | Why? |
| Sexual Dysfunction, Physiological | 1 | 2018 | 89 | 0.16 | Why? |
| Fingolimod Hydrochloride | 1 | 2018 | 217 | 0.16 | Why? |
| Drug Administration Schedule | 3 | 2018 | 2324 | 0.16 | Why? |
| Clinical Trials, Phase I as Topic | 1 | 2018 | 242 | 0.16 | Why? |
| Mice, Nude | 1 | 2017 | 340 | 0.16 | Why? |
| Government Agencies | 1 | 2018 | 248 | 0.16 | Why? |
| Adolescent | 14 | 2020 | 86841 | 0.16 | Why? |
| Pelvic Organ Prolapse | 1 | 2017 | 71 | 0.16 | Why? |
| Cytochrome P-450 Enzyme System | 1 | 2017 | 144 | 0.16 | Why? |
| Laser Therapy | 1 | 2019 | 158 | 0.16 | Why? |
| Clinical Decision-Making | 3 | 2019 | 3755 | 0.16 | Why? |
| Proportional Hazards Models | 3 | 2018 | 6543 | 0.16 | Why? |
| Laparoscopy | 2 | 2018 | 1532 | 0.15 | Why? |
| Attitude of Health Personnel | 1 | 2014 | 4741 | 0.15 | Why? |
| Peripheral Nerve Injuries | 1 | 2017 | 114 | 0.15 | Why? |
| Immunoglobulins | 2 | 2018 | 811 | 0.15 | Why? |
| Vagina | 1 | 2018 | 327 | 0.15 | Why? |
| Endoplasmic Reticulum Stress | 1 | 2018 | 253 | 0.15 | Why? |
| Global Health | 6 | 2020 | 13911 | 0.15 | Why? |
| Network Meta-Analysis | 1 | 2017 | 426 | 0.15 | Why? |
| Adaptive Immunity | 2 | 2018 | 2585 | 0.15 | Why? |
| Drug Therapy | 1 | 2018 | 280 | 0.15 | Why? |
| Prevalence | 5 | 2020 | 25773 | 0.14 | Why? |
| Peptide Library | 1 | 2018 | 564 | 0.14 | Why? |
| Enzyme-Linked Immunosorbent Assay | 3 | 2018 | 7868 | 0.14 | Why? |
| Disease Models, Animal | 4 | 2018 | 10998 | 0.14 | Why? |
| Arthritis, Rheumatoid | 3 | 2017 | 2043 | 0.14 | Why? |
| Drug Therapy, Combination | 6 | 2019 | 7268 | 0.14 | Why? |
| Spondylarthritis | 1 | 2017 | 174 | 0.14 | Why? |
| Incidence | 5 | 2020 | 25622 | 0.14 | Why? |
| European Union | 1 | 2018 | 565 | 0.14 | Why? |
| Pharmacovigilance | 1 | 2019 | 501 | 0.14 | Why? |
| Transfection | 1 | 2017 | 864 | 0.14 | Why? |
| Cross-Over Studies | 1 | 2017 | 867 | 0.14 | Why? |
| RNA Interference | 1 | 2017 | 534 | 0.13 | Why? |
| Colectomy | 1 | 2017 | 327 | 0.13 | Why? |
| Cardiovascular Diseases | 1 | 2019 | 11497 | 0.13 | Why? |
| Interferon-gamma | 2 | 2017 | 2711 | 0.13 | Why? |
| Maintenance Chemotherapy | 3 | 2019 | 133 | 0.13 | Why? |
| Intestine, Small | 1 | 2017 | 336 | 0.13 | Why? |
| Immunocompromised Host | 3 | 2020 | 5150 | 0.13 | Why? |
| Sexual Health | 1 | 2019 | 419 | 0.13 | Why? |
| Abdomen | 1 | 2017 | 424 | 0.13 | Why? |
| Biomarkers | 5 | 2019 | 23361 | 0.13 | Why? |
| Reproductive Health | 1 | 2019 | 473 | 0.13 | Why? |
| Data Interpretation, Statistical | 1 | 2018 | 657 | 0.13 | Why? |
| Prospective Studies | 10 | 2020 | 43301 | 0.13 | Why? |
| Trauma Severity Indices | 1 | 2013 | 176 | 0.13 | Why? |
| Aged | 18 | 2021 | 215776 | 0.13 | Why? |
| Infertility, Male | 1 | 2018 | 322 | 0.12 | Why? |
| Risk Reduction Behavior | 1 | 2020 | 946 | 0.12 | Why? |
| Standard of Care | 1 | 2020 | 1297 | 0.12 | Why? |
| Publications | 1 | 2018 | 463 | 0.12 | Why? |
| Lactobacillus | 1 | 2013 | 92 | 0.12 | Why? |
| Environment | 1 | 2019 | 769 | 0.12 | Why? |
| Physician-Patient Relations | 2 | 2020 | 1266 | 0.12 | Why? |
| Iron | 1 | 2018 | 619 | 0.12 | Why? |
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 8811 | 0.12 | Why? |
| Injections, Subcutaneous | 3 | 2019 | 647 | 0.12 | Why? |
| Metagenomics | 1 | 2018 | 823 | 0.12 | Why? |
| New York | 1 | 2020 | 2488 | 0.12 | Why? |
| Vascular Cell Adhesion Molecule-1 | 2 | 2018 | 121 | 0.12 | Why? |
| Abdominal Pain | 2 | 2019 | 858 | 0.12 | Why? |
| Time Factors | 7 | 2019 | 31397 | 0.11 | Why? |
| Piroxicam | 1 | 2011 | 20 | 0.11 | Why? |
| Vaccines, Attenuated | 1 | 2017 | 952 | 0.11 | Why? |
| Leukocytes | 1 | 2018 | 1046 | 0.11 | Why? |
| Pneumococcal Vaccines | 1 | 2017 | 571 | 0.11 | Why? |
| Self-Management | 1 | 2017 | 546 | 0.11 | Why? |
| United States Food and Drug Administration | 1 | 2018 | 1276 | 0.11 | Why? |
| Kaplan-Meier Estimate | 2 | 2018 | 4260 | 0.11 | Why? |
| Opportunistic Infections | 1 | 2017 | 602 | 0.11 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.11 | Why? |
| Risk Assessment | 6 | 2021 | 25439 | 0.10 | Why? |
| Pneumococcal Infections | 1 | 2017 | 562 | 0.10 | Why? |
| Activities of Daily Living | 1 | 2019 | 1530 | 0.10 | Why? |
| Mice, Knockout | 2 | 2018 | 1815 | 0.10 | Why? |
| Patient Education as Topic | 1 | 2020 | 1476 | 0.10 | Why? |
| Autophagy | 1 | 2018 | 960 | 0.10 | Why? |
| Retrospective Studies | 13 | 2019 | 105322 | 0.10 | Why? |
| Infusions, Intravenous | 3 | 2019 | 1224 | 0.10 | Why? |
| Biopsy | 1 | 2019 | 2811 | 0.10 | Why? |
| Cells, Cultured | 2 | 2021 | 5835 | 0.10 | Why? |
| Sulfonamides | 1 | 2018 | 1294 | 0.10 | Why? |
| Life Style | 2 | 2019 | 2708 | 0.10 | Why? |
| Ferritins | 1 | 2018 | 2055 | 0.10 | Why? |
| Comorbidity | 5 | 2020 | 34796 | 0.10 | Why? |
| Practice Guidelines as Topic | 5 | 2020 | 15421 | 0.09 | Why? |
| Biomedical Research | 2 | 2020 | 5270 | 0.09 | Why? |
| Multivariate Analysis | 2 | 2017 | 5440 | 0.09 | Why? |
| Health Care Surveys | 2 | 2020 | 2942 | 0.09 | Why? |
| Critical Pathways | 1 | 2019 | 1587 | 0.09 | Why? |
| Health Surveys | 1 | 2020 | 2841 | 0.09 | Why? |
| Databases, Factual | 3 | 2018 | 6248 | 0.09 | Why? |
| Patient Selection | 2 | 2020 | 4560 | 0.09 | Why? |
| Environmental Exposure | 1 | 2019 | 1558 | 0.09 | Why? |
| Adrenal Cortex Hormones | 4 | 2019 | 6537 | 0.09 | Why? |
| Pregnancy Outcome | 2 | 2019 | 3803 | 0.09 | Why? |
| Skin Diseases | 2 | 2019 | 2509 | 0.09 | Why? |
| Gene Expression Profiling | 1 | 2019 | 3788 | 0.08 | Why? |
| Drug Delivery Systems | 1 | 2017 | 1365 | 0.08 | Why? |
| Premature Birth | 1 | 2019 | 2151 | 0.08 | Why? |
| World Health Organization | 1 | 2020 | 4213 | 0.08 | Why? |
| Research Design | 2 | 2020 | 5830 | 0.08 | Why? |
| Health Services Accessibility | 2 | 2020 | 10697 | 0.08 | Why? |
| Quality of Health Care | 1 | 2018 | 1948 | 0.08 | Why? |
| Surveys and Questionnaires | 5 | 2020 | 43792 | 0.08 | Why? |
| Leukocyte Adherence Inhibition Test | 1 | 2005 | 4 | 0.08 | Why? |
| Intention to Treat Analysis | 2 | 2018 | 673 | 0.08 | Why? |
| Interleukin-17 | 1 | 2011 | 602 | 0.08 | Why? |
| Antirheumatic Agents | 2 | 2017 | 3023 | 0.08 | Why? |
| Biliary Tract Diseases | 1 | 2005 | 60 | 0.07 | Why? |
| Peptides | 1 | 2018 | 2513 | 0.07 | Why? |
| Guidelines as Topic | 1 | 2018 | 2844 | 0.07 | Why? |
| Diagnosis, Differential | 1 | 2020 | 7220 | 0.07 | Why? |
| Drug Evaluation, Preclinical | 1 | 2017 | 3347 | 0.07 | Why? |
| France | 5 | 2020 | 12074 | 0.07 | Why? |
| Prognosis | 5 | 2021 | 32490 | 0.07 | Why? |
| Viruses | 1 | 2018 | 2238 | 0.07 | Why? |
| Europe | 3 | 2020 | 12702 | 0.07 | Why? |
| Risk | 1 | 2017 | 5288 | 0.07 | Why? |
| Dose-Response Relationship, Drug | 3 | 2019 | 3776 | 0.07 | Why? |
| Intercellular Adhesion Molecule-1 | 1 | 2005 | 189 | 0.07 | Why? |
| Inpatients | 1 | 2020 | 5161 | 0.07 | Why? |
| Perception | 3 | 2021 | 2827 | 0.07 | Why? |
| Folic Acid | 1 | 2005 | 172 | 0.06 | Why? |
| Chronic Disease | 1 | 2018 | 5139 | 0.06 | Why? |
| Pregnancy | 4 | 2019 | 23879 | 0.06 | Why? |
| Evidence-Based Medicine | 1 | 2017 | 3228 | 0.06 | Why? |
| Disease Progression | 3 | 2017 | 13580 | 0.06 | Why? |
| Breast Neoplasms | 1 | 2021 | 3633 | 0.06 | Why? |
| Case-Control Studies | 2 | 2021 | 17671 | 0.06 | Why? |
| China | 2 | 2020 | 50654 | 0.06 | Why? |
| Chemokine CCL2 | 1 | 2005 | 389 | 0.06 | Why? |
| Ambulatory Care | 1 | 2020 | 4947 | 0.06 | Why? |
| Child | 4 | 2020 | 70012 | 0.06 | Why? |
| Reference Values | 1 | 2005 | 795 | 0.06 | Why? |
| Eye Diseases | 2 | 2019 | 1150 | 0.06 | Why? |
| Tuberculosis | 1 | 2017 | 2895 | 0.05 | Why? |
| Microcirculation | 1 | 2005 | 447 | 0.05 | Why? |
| Influenza Vaccines | 1 | 2017 | 2941 | 0.05 | Why? |
| Cytokines | 2 | 2021 | 15010 | 0.05 | Why? |
| Late Onset Disorders | 1 | 2019 | 30 | 0.05 | Why? |
| Hospitals | 1 | 2020 | 11793 | 0.05 | Why? |
| Neoplasms, Experimental | 1 | 2019 | 67 | 0.05 | Why? |
| Lymphatic Vessels | 1 | 2019 | 43 | 0.05 | Why? |
| Dimensional Measurement Accuracy | 1 | 2018 | 56 | 0.05 | Why? |
| Tertiary Care Centers | 1 | 2017 | 8248 | 0.05 | Why? |
| Sensitivity and Specificity | 2 | 2017 | 22971 | 0.05 | Why? |
| Cost-Benefit Analysis | 2 | 2019 | 2259 | 0.05 | Why? |
| Stress, Psychological | 2 | 2019 | 10231 | 0.05 | Why? |
| Surgical Mesh | 1 | 2018 | 55 | 0.05 | Why? |
| Smad7 Protein | 1 | 2018 | 32 | 0.05 | Why? |
| Immunity, Innate | 1 | 2017 | 6570 | 0.05 | Why? |
| Physicians | 1 | 2018 | 4214 | 0.04 | Why? |
| Anatomy, Cross-Sectional | 1 | 2017 | 7 | 0.04 | Why? |
| Aminosalicylic Acid | 1 | 2017 | 8 | 0.04 | Why? |
| Nasopharyngitis | 1 | 2017 | 16 | 0.04 | Why? |
| Cancer Vaccines | 1 | 2019 | 136 | 0.04 | Why? |
| Certolizumab Pegol | 1 | 2017 | 36 | 0.04 | Why? |
| Urologic Diseases | 1 | 2005 | 860 | 0.04 | Why? |
| Societies, Medical | 3 | 2020 | 6907 | 0.04 | Why? |
| Mice, Inbred C57BL | 2 | 2019 | 5542 | 0.04 | Why? |
| Organs at Risk | 1 | 2017 | 48 | 0.04 | Why? |
| Aged, 80 and over | 4 | 2021 | 88759 | 0.04 | Why? |
| Unfolded Protein Response | 1 | 2018 | 134 | 0.04 | Why? |
| Retreatment | 1 | 2017 | 186 | 0.04 | Why? |
| Organ Sparing Treatments | 1 | 2017 | 91 | 0.04 | Why? |
| Polypharmacy | 1 | 2019 | 347 | 0.04 | Why? |
| Operative Time | 1 | 2018 | 450 | 0.04 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.04 | Why? |
| International Agencies | 1 | 2018 | 202 | 0.04 | Why? |
| Flow Cytometry | 1 | 2005 | 2393 | 0.04 | Why? |
| STAT Transcription Factors | 1 | 2017 | 173 | 0.04 | Why? |
| Reproducibility of Results | 3 | 2019 | 11304 | 0.04 | Why? |
| Cost Savings | 1 | 2018 | 296 | 0.04 | Why? |
| Mice | 2 | 2018 | 21357 | 0.04 | Why? |
| Family Relations | 1 | 2019 | 288 | 0.04 | Why? |
| Databases, Pharmaceutical | 1 | 2018 | 345 | 0.04 | Why? |
| Muscle Weakness | 1 | 2019 | 406 | 0.04 | Why? |
| Cecum | 1 | 2015 | 63 | 0.04 | Why? |
| Drainage | 1 | 2018 | 414 | 0.04 | Why? |
| Edema | 1 | 2018 | 333 | 0.04 | Why? |
| Transplantation, Homologous | 1 | 2017 | 757 | 0.04 | Why? |
| Depression | 1 | 2019 | 14116 | 0.04 | Why? |
| Spondylitis, Ankylosing | 1 | 2017 | 231 | 0.03 | Why? |
| Immunoglobulin G | 1 | 2018 | 21571 | 0.03 | Why? |
| Chi-Square Distribution | 1 | 2017 | 961 | 0.03 | Why? |
| Administration, Intravenous | 1 | 2018 | 1115 | 0.03 | Why? |
| Goals | 1 | 2017 | 335 | 0.03 | Why? |
| DNA, Bacterial | 1 | 2018 | 835 | 0.03 | Why? |
| Endothelium, Vascular | 1 | 2005 | 1751 | 0.03 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.03 | Why? |
| Liver Function Tests | 1 | 2020 | 1325 | 0.03 | Why? |
| Serum Albumin | 1 | 2017 | 571 | 0.03 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.03 | Why? |
| Anxiety | 1 | 2019 | 17311 | 0.03 | Why? |
| Prednisone | 1 | 2017 | 652 | 0.03 | Why? |
| Ileum | 1 | 2015 | 233 | 0.03 | Why? |
| Weight Loss | 1 | 2019 | 826 | 0.03 | Why? |
| Cyclosporine | 1 | 2017 | 449 | 0.03 | Why? |
| Protective Factors | 1 | 2019 | 1720 | 0.03 | Why? |
| Risk Management | 1 | 2020 | 1044 | 0.03 | Why? |
| Thromboembolism | 1 | 2005 | 2101 | 0.03 | Why? |
| Patient Reported Outcome Measures | 1 | 2018 | 912 | 0.03 | Why? |
| Virus Attachment | 1 | 2020 | 1259 | 0.03 | Why? |
| Influenza, Human | 1 | 2017 | 10779 | 0.03 | Why? |
| Hygiene | 1 | 2019 | 987 | 0.03 | Why? |
| Dysbiosis | 1 | 2018 | 685 | 0.03 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.03 | Why? |
| Interleukins | 1 | 2017 | 762 | 0.03 | Why? |
| HIV Infections | 1 | 2017 | 11620 | 0.03 | Why? |
| Drug Monitoring | 1 | 2018 | 1408 | 0.03 | Why? |
| Tomography, X-Ray Computed | 1 | 2017 | 25144 | 0.03 | Why? |
| Liver Diseases | 1 | 2005 | 2698 | 0.03 | Why? |
| Cohort Studies | 3 | 2019 | 36005 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2018 | 3395 | 0.02 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 1261 | 0.02 | Why? |
| Precision Medicine | 1 | 2019 | 1477 | 0.02 | Why? |
| Israel | 1 | 2017 | 2751 | 0.02 | Why? |
| Mice, Inbred BALB C | 1 | 2019 | 5814 | 0.02 | Why? |
| Neoplasms | 1 | 2017 | 17251 | 0.02 | Why? |
| Workload | 1 | 2019 | 1887 | 0.02 | Why? |
| Sleep Wake Disorders | 1 | 2019 | 1463 | 0.02 | Why? |
| Macrophages | 1 | 2019 | 2784 | 0.02 | Why? |
| New York City | 1 | 2021 | 7432 | 0.02 | Why? |
| Autoimmune Diseases | 1 | 2020 | 1996 | 0.02 | Why? |
| Emotions | 1 | 2019 | 2418 | 0.02 | Why? |
| Headache | 1 | 2017 | 2257 | 0.02 | Why? |
| Health Care Rationing | 1 | 2020 | 2558 | 0.02 | Why? |
| Decision Making | 1 | 2020 | 3132 | 0.02 | Why? |
| Odds Ratio | 1 | 2017 | 5861 | 0.02 | Why? |
| Internationality | 1 | 2018 | 3297 | 0.02 | Why? |
| Anti-Bacterial Agents | 2 | 2018 | 10083 | 0.02 | Why? |
| Serine Endopeptidases | 1 | 2020 | 4606 | 0.02 | Why? |
| Computational Biology | 1 | 2018 | 4514 | 0.01 | Why? |
| Vaccination | 2 | 2019 | 19050 | 0.01 | Why? |
| Emergency Medical Services | 1 | 2019 | 3557 | 0.01 | Why? |
| United States | 2 | 2019 | 46150 | 0.01 | Why? |
| Mobile Applications | 1 | 2017 | 3032 | 0.01 | Why? |
| Immunoassay | 1 | 2017 | 4485 | 0.01 | Why? |
| Virus Internalization | 1 | 2020 | 7921 | 0.01 | Why? |
| C-Reactive Protein | 1 | 2017 | 7972 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2021 | 11041 | 0.01 | Why? |
| Viral Load | 1 | 2021 | 15850 | 0.01 | Why? |
| Registries | 1 | 2020 | 12327 | 0.01 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.01 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.01 | Why? |
| Patient Acceptance of Health Care | 1 | 2017 | 5002 | 0.01 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.01 | Why? |
| Social Media | 1 | 2017 | 5798 | 0.01 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2019 | 53120 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 37182 | 0.01 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.01 | Why? |